Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial
Top Cited Papers
- 1 September 2015
- journal article
- research article
- Published by Elsevier BV in Pharmacological Research
- Vol. 99, 74-81
- https://doi.org/10.1016/j.phrs.2015.05.009
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (30972469, 81273059)
- Science and Technology Key Project Foundation of Chongqing (2011AB5040)
- National Science-technology Support Plan Projects Foundation of China (2012BAI35B02)
This publication has 38 references indexed in Scilit:
- Dihydromyricetin improves skeletal muscle insulin resistance by inducing autophagy via the AMPK signaling pathwayMolecular and Cellular Endocrinology, 2015
- Dihydromyricetin Improves Physical Performance under Simulated High AltitudeMedicine & Science in Sports & Exercise, 2014
- Ampelopsin Induces Cell Growth Inhibition and Apoptosis in Breast Cancer Cells through ROS Generation and Endoplasmic Reticulum Stress PathwayPLOS ONE, 2014
- Nonalcoholic fatty liver disease: Current and potential therapiesLife Sciences, 2013
- Obesity, diabetes mellitus, and liver fibrosisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- CHARACTERIZATION AND ANTIOXIDANT ACTIVITY OF FLAVONOID-RICH EXTRACTS FROM LEAVES OF AMPELOPSIS GROSSEDENTATAJournal of Food Biochemistry, 2009
- Epidemiology of non-alcoholic fatty liver disease in ChinaJournal of Hepatology, 2009
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisJournal of Hepatology, 2006
- Mouse models in non‐alcoholic fatty liver disease and steatohepatitis researchInternational Journal of Experimental Pathology, 2006
- Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: A manifestation of lipotoxicity?Journal of Hepatology, 2002